Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Withdrawal, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Egalet® Abuse-deterrent, Extended-release (ADER) Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Low Back Pain

NCT02716857 is registered in ClinicalTrials.gov with Egalet Ltd as lead sponsor.

NCT NCT02716857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02716857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Withdrawal, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Egalet® Abuse-deterrent, Extended-release (ADER) Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Low Back Pain
Lead sponsor
Egalet Ltd
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2016
Completion date
November 30, 2017
Enrollment
549 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe chronic low back pain